GURU.Markets stock price, segment price, and overall market index valuation
The company's share price AEON Biopharma
Shares of AEON Biopharma, a biotech company developing botulinum toxin for therapeutic use, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma neurology
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic applications, such as the treatment of migraines and other neurological disorders. We have classified the company in the Pharma: Neurology segment. The chart below shows the dynamics in this segment.
Broad Market Index - GURU.Markets
AEON Biopharma is a biopharmaceutical company developing botulinum toxin-based drugs for therapeutic use, such as migraine treatment. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how AEON compares to it.
Change in the price of a company, segment, and market as a whole per day
AEON - Daily change in the company's share price AEON Biopharma
AEON Biopharma's daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its botulinum toxin for therapeutic use.
Daily change in the price of a set of shares in a market segment - Pharma neurology
AEON Biopharma is developing botulinum toxin for therapeutic use in neurology. This highly specialized pharmaceutical segment has its own dynamics. The chart below reflects the average daily volatility in the sector, allowing investors to compare AEON's stock performance with industry peers.
Daily change in the price of a broad market stock, index - GURU.Markets
AEON Biopharma is a biotech company working on the treatment of neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the overall stock market's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization AEON Biopharma
AEON Biopharma's year-to-date performance is a story about the development of a botulinum toxin for therapeutic use. Its 12-month market cap depends entirely on clinical trial data for its drug for the treatment of migraines and other neurological disorders. Success could open up a huge market for the company, dominated by Botox.
Annual dynamics of market capitalization of the market segment - Pharma neurology
AEON, a biotech company developing botulinum toxin for therapeutic applications, is betting on the expansion of this market. Its performance relative to the sector will reveal how much investors believe in its ability to compete with giants like AbbVie (Botox) in this lucrative niche.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
AEON Biopharma, which specializes in the therapeutic use of botulinum toxin, operates in a niche but promising market. Comparing its annual market capitalization to the overall market allows us to assess how the company competes with aesthetic medicine giants and the success of its strategy to expand the drug's use in treating various conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization AEON Biopharma
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic applications. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its programs is a key event for investors.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botulinum toxin for therapeutic use. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its drugs for the treatment of migraines and other neurological disorders in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
AEON Biopharma is a biotech company developing botulinum toxin for therapeutic purposes. Its shares are buoyed by anticipation of clinical trial results. The chart shows that monthly price fluctuations are unrelated to overall market trends, but rather reflect specific scientific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization AEON Biopharma
AEON Biopharma is developing botulinum toxin for therapeutic use, putting it in direct competition with aesthetic medicine giants. The company's weekly share price performance reflects clinical trial data and news that could impact its chances of carving out a niche in the multi-billion dollar market.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
AEON Biopharma is developing a botulinum toxin for therapeutic use in neurology. Its stock price is closely linked to clinical trial results and FDA decisions. The chart shows whether its stock follows the overall sector trend or follows its own news cycle.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
AEON Biopharma is a biotech company developing botulinum toxin. Like many companies in this sector, its shares are awaiting clinical trial results. The chart will show how its weekly performance is completely disconnected from overall market trends and driven by internal events.
Market capitalization of the company, segment and market as a whole
AEON - Market capitalization of the company AEON Biopharma
AEON Biopharma's market capitalization chart reflects investors' bets on the therapeutic potential of botulinum toxin beyond cosmetics. Its dynamics reflect the market's belief that its drugs will be able to treat migraines, cervical dystonia, and other neurological disorders. The company's value is an estimate of the potential of this well-known toxin in new medical fields.
AEON - Share of the company's market capitalization AEON Biopharma within the market segment - Pharma neurology
AEON Biopharma specializes in the therapeutic use of botulinum toxin. Its market share in the pharmaceutical sector reflects its narrow but deep specialization. The company's market capitalization is a bet on the success of its drugs for the treatment of migraines and other neurological conditions, where it competes with giants.
Market capitalization of the market segment - Pharma neurology
Below is a chart reflecting the combined weight of the entire neurological pharmaceutical sector. For AEON Biopharma, which is developing a botulinum toxin for therapeutic use, this line represents the potential market. The rising chart demonstrates investors' belief that known molecules can find new applications in the treatment of complex neurological conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
AEON Biopharma is developing botulinum toxin for therapeutic use in neurology. Its market capitalization relative to the pharmaceutical market reflects the potential of a well-known molecule in new areas. This market share reflects the expanded use of existing drugs.
Book value capitalization of the company, segment and market as a whole
AEON - Book value capitalization of the company AEON Biopharma
AEON Biopharma is developing botulinum toxin for therapeutic purposes. Its book value is its financial resources for research. It consists of cash that allows the company to conduct expensive clinical trials. How has this research capital changed? The chart below shows this trend.
AEON - Share of the company's book capitalization AEON Biopharma within the market segment - Pharma neurology
AEON Biopharma is developing botulinum toxin for therapeutic use. Its scientific work requires a sophisticated and secure infrastructure: specialized laboratories and manufacturing facilities for working with this biological agent. The chart shows the company's share of the physical infrastructure for this niche pharmaceutical segment.
Market segment balance sheet capitalization - Pharma neurology
AEON Biopharma is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. AEON focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
AEON Biopharma's book value is not derived from its production lines, but primarily from capital invested in clinical trials of botulinum toxin for therapeutic use in neurology. Its assets reflect the financial resources available for developing new treatments. The chart illustrates the scale of this specialized pharmaceutical company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - AEON Biopharma
AEON Biopharma is developing a botulinum toxin for therapeutic use. Its market capitalization is based on the potential of this well-known drug in new medical niches. Investors are assessing its ability to secure regulatory approval and capture market share.
Market to book capitalization ratio in a market segment - Pharma neurology
AEON Biopharma is a company developing a botulinum toxin for therapeutic purposes. Its high valuation on this chart is solely a bet on the success of clinical trials and regulatory approval. Investors are buying not tangible assets, but the potential for a new medical application for a well-known substance.
Market to book capitalization ratio for the market as a whole
AEON Biopharma is developing botulinum toxin-based drugs. For companies like these, their primary assets are not laboratories, but intellectual property and clinical trial results. This metric helps understand how the market evaluates the potential for multibillion-dollar sales of a future drug compared to current tangible assets.
Debts of the company, segment and market as a whole
AEON - Company debts AEON Biopharma
AEON Biopharma, a clinical-stage biopharmaceutical company developing a botulinum toxin for therapeutic use, is using raised capital to finance expensive and time-consuming clinical trials. This chart illustrates how the company is investing in efforts to bring a new medical product to market, which requires significant upfront costs.
Market segment debts - Pharma neurology
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic use, specifically for the treatment of migraines and other neurological conditions. This chart illustrates how the company, while in the clinical stage, is funding its expensive research to compete in a market already occupied by established leaders with similar products.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio AEON Biopharma
AEON Biopharma is developing a botulinum toxin for therapeutic use in neurology. Conducting costly and lengthy clinical trials to obtain regulatory approval requires significant funding. This chart shows the company's use of debt, reflecting its financial risks on the path to commercialization.
Market segment debt to market segment book capitalization - Pharma neurology
AEON Biopharma is developing a botulinum toxin for therapeutic use in neurology. Bringing a new drug to market requires significant investments in clinical trials. This chart shows how the company finances this process, relating its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
AEON Biopharma specializes in developing botulinum toxin for therapeutic use in neurology. Bringing a new drug to market is a lengthy and capital-intensive process. How heavily does the company rely on debt financing? This chart, reflecting the overall debt burden in the economy, allows us to assess the risks of its financial strategy in this competitive market.
P/E of the company, segment and market as a whole
P/E - AEON Biopharma
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic use, specifically for the treatment of migraines and other neurological disorders. This chart shows how investors assess its chances of competing with established brands like Botox in the medical market.
P/E of the market segment - Pharma neurology
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic, non-cosmetic, applications, specifically for the treatment of neurological disorders. This chart illustrates the average valuation in the neurological pharmaceutical sector, where investors evaluate the potential for new applications of known molecules.
P/E of the market as a whole
AEON Biopharma is a biopharmaceutical company specializing in the development of botulinum toxin for therapeutic use, particularly in the treatment of neurological disorders. This chart reflects investors' overall risk appetite. It helps understand whether AEON's valuation is based on the potential of its drugs or whether it moves in line with overall sentiment in the pharmaceutical sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company AEON Biopharma
AEON Biopharma is developing botulinum toxin for therapeutic use, particularly for the treatment of neurological disorders such as migraine. The company's future depends on the success of clinical trials. This timeline reflects investor expectations regarding the approval and commercial potential of their drug in the vast therapeutic market.
%20P%2FE%20AEON%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-AEON-Biopharma&v=1772664606398 "Chart of the company's future (projected) P/E AEON Biopharma")
Future (projected) P/E of the market segment - Pharma neurology
AEON Biopharma is developing botulinum toxin for therapeutic use in neurology. The company is targeting a large but competitive market. Average profitability projections for the biopharmaceutical segment are shown here. This allows us to assess how optimistic the market is about AEON's ability to fill its niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772664606422 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
AEON Biopharma is developing a botulinum toxin for therapeutic use, specifically for the treatment of neurological disorders. It is a highly specialized pharmaceutical company. This overall risk appetite chart helps understand the market's willingness to invest in biotech companies with a single promising product in development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772664606435 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit AEON Biopharma
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic use in the treatment of neurological disorders such as migraine. Its financial indicators include clinical trial expenses. This chart illustrates the investment phase required to bring a new drug to market.
Profit of companies in the market segment - Pharma neurology
AEON Biopharma specializes in developing botulinum toxin for therapeutic use in the treatment of neurological disorders such as migraine and cervical dystonia. This chart shows the overall profitability of the neurological pharmaceutical sector, where there is a significant need for new, effective and safe treatments for chronic conditions.
Overall market profit
AEON Biopharma develops botulinum toxins for therapeutic use in neurology. The company's prospects depend on the success of clinical trials and regulatory approval. Demand for treatments for neurological disorders is driven by medical needs, not economic conditions, making AEON's business independent of market cycles, as illustrated in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company AEON Biopharma
AEON Biopharma specializes in developing botulinum toxin for therapeutic use, particularly for the treatment of migraines and other neurological disorders. Future profits depend on the success of clinical trials and competition with existing drugs. This chart reflects analyst expectations regarding the company's potential to carve out a niche in the neurotoxin market.
%20profit%20of%20the%20company%20AEON%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-AEON-Biopharma&v=1772664606550 "Graph of future (projected) profit of the company AEON Biopharma")
Future (predicted) profit of companies in the market segment - Pharma neurology
AEON Biopharma specializes in developing botulinum toxin for therapeutic use in the treatment of neurological disorders such as migraine and cervical dystonia. The company's future depends on the success of clinical trials. This chart shows revenue projections for the neurological pharmaceutical segment, providing context for assessing AEON's potential in this market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772664606635 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic use. Its prospects depend on the success of clinical trials. This economic outlook affects the overall investment climate in the biotech sector, which affects the availability of financing for companies like AEON.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772664606662 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - AEON Biopharma
AEON Biopharma is developing a botulinum toxin for therapeutic use. Being in the development stage, the company may not have stable revenue. This chart reflects investors' assessment of its scientific potential and addressable market size. The multiple here is more an indicator of confidence in future sales than a valuation of the current business.
P/S market segment - Pharma neurology
AEON Biopharma develops botulinum toxin-based therapeutics for the treatment of neurological disorders such as migraine and cervical dystonia. The company aims to capture a significant share of the large and growing neurotoxin market. This chart reflects the average revenue estimate for the pharmaceutical sector, helping to assess the commercial potential of AEON's developments.
P/S of the market as a whole
AEON Biopharma is developing botulinum toxin for therapeutic use in the treatment of various neurological conditions, such as migraine. This chart demonstrates that the valuation of clinical-stage biopharmaceutical companies like AEON primarily reflects investors' confidence in the future success of their drugs, rather than their current financial performance and market performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company AEON Biopharma
AEON Biopharma is developing a botulinum toxin for therapeutic use in the treatment of neurological disorders. Estimating future revenue is key for the company at the clinical stage. It reflects investor expectations regarding the success of clinical trials and the potential of its drug to compete in the existing but large market for therapeutic neurotoxins.
%20P%2FS%20AEON%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-AEON-Biopharma&v=1772664606688 "The graph of the company's future (projected) P/S AEON Biopharma")
Future (projected) P/S of the market segment - Pharma neurology
AEON Biopharma specializes in developing botulinum toxin for therapeutic use, specifically for the treatment of migraines and other neurological disorders. This chart compares the company's estimated future sales with industry expectations. It shows whether investors believe its drug can capture a significant share of the competitive neurotoxin market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772664606801 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
AEON Biopharma is developing botulinum toxin for therapeutic use in the treatment of migraines and other neurological disorders. The company's success depends on clinical trials and competition with existing drugs. This market forecast chart reflects investor confidence in the growth of the pharmaceutical market and the demand for new treatments for chronic diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772664606810 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales AEON Biopharma
This chart shows the revenue of AEON Biopharma, a company developing a botulinum toxin for therapeutic use in neurology. While in clinical trials, the company may not have any sales revenue. Any revenue is likely related to licensing agreements, and future success depends on the approval and commercialization of the drug.
Sales of companies in the market segment - Pharma neurology
AEON Biopharma is a biotechnology company specializing in the development of botulinum toxin for therapeutic use. Currently in clinical trials, the company has no sales revenue. Its future revenue will depend entirely on the successful commercialization of drugs for the treatment of migraines and other neurological disorders.
Overall market sales
AEON Biopharma develops botulinum toxin for therapeutic use in neurology. The company operates in a highly specialized field of medicine, where demand is driven by patient needs rather than economic cycles. This overall market performance chart serves only as a backdrop for a company whose value is derived from scientific research and clinical success.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company AEON Biopharma
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic use in the treatment of neurological disorders such as migraine and cervical dystonia. Future revenue is dependent on the success of clinical trials. This chart reflects analysts' sales projections for the drug, based on the target market size and its efficacy.
%20sales%20of%20the%20company%20AEON%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-AEON-Biopharma&v=1772664606856 "Schedule of future (projected) sales of the company AEON Biopharma")
Future (projected) sales of companies in the market segment - Pharma neurology
AEON Biopharma is developing botulinum toxin for therapeutic applications, such as the treatment of migraines. This chart shows the revenue forecast for the entire neurotoxin market. Is an expansion of therapeutic indications and increased demand expected, supporting the entire industry? This determines the overall outlook for such developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772664606875 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
AEON Biopharma is developing botulinum toxin for therapeutic use in neurology. The company's success depends on clinical trials and regulatory approval. The need for treatments for neurological conditions is not dependent on economic cycles, so this graph, reflecting consumer spending, has minimal impact on AEON's fundamental business drivers.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772664606887 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality AEON Biopharma
AEON Biopharma is developing botulinum toxin for therapeutic use in the treatment of neurological disorders. This chart shows the company's financial performance at the clinical trial stage. Profitability is a long-term prospect and will depend on successful research results and regulatory approval for entry into the multi-billion dollar market.
Market segment marginality - Pharma neurology
AEON Biopharma is a clinical-stage biopharmaceutical company developing botulinum toxin for therapeutic use in neurology. While in the research phase, the company incurs significant R&D expenses. This chart shows its current financial metrics, with profitability a long-term goal dependent on the success of clinical trials and FDA approval.
Market marginality as a whole
AEON Biopharma, developing botulinum toxin for therapeutic use in neurology, operates at the intersection of science and commerce. This gross profitability chart reflects the economic environment influencing R&D funding and future insurance pricing policies, which will determine the drug's commercial success.
Employees in the company, segment and market as a whole
Number of employees in the company AEON Biopharma
AEON Biopharma is developing botulinum toxin for therapeutic use. The company's team consists of scientists and clinical research specialists. This graph illustrates the development phase: staff growth is directly related to the scale and progress of clinical trials, which are the most capital-intensive stage on the path to drug approval.
Share of the company's employees AEON Biopharma within the market segment - Pharma neurology
AEON Biopharma specializes in the therapeutic use of botulinum toxin for the treatment of various diseases. The development and clinical trials of these drugs require a team of highly qualified scientists and clinicians. This figure reflects the company's market share in the narrow neuroscience niche, demonstrating the scale of its research program.
Number of employees in the market segment - Pharma neurology
AEON Biopharma specializes in the therapeutic use of botulinum toxin for the treatment of neurological disorders. This chart shows employment in the neurological pharmaceutical sector. Growth in this area reflects advances in understanding nervous system diseases and the search for new applications for known molecules, which is AEON's strategy.
Number of employees in the market as a whole
AEON Biopharma is developing botulinum toxin for therapeutic use. This is a highly specialized field, where the team's growth depends on success in clinical trials. This chart shows the big picture, while AEON represents the world of biotech, where employment is driven by scientific discoveries rather than macroeconomic trends.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company AEON Biopharma (AEON)
AEON Biopharma specializes in developing botulinum toxin for therapeutic purposes. As with most biotech companies, intellectual property is a key asset. This chart helps understand the market value placed on their clinical developments and patents. A high value indicates that each employee accounts for a significant share of expected future profits.
%20of%20the%20company%20AEON%20Biopharma%20(AEON)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-AEON-Biopharma-AEON&v=1772664607036 "Chart of market capitalization per employee (in thousands of dollars) of the company AEON Biopharma (AEON)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
AEON Biopharma (AEON) specializes in developing botulinum toxin for therapeutic use. In the pharmaceutical industry, this metric reflects not current sales, but the potential of future products. A high cost per employee may indicate investors' confidence in the successful completion of clinical trials and a future blockbuster.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772664607054 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
AEON Biopharma is a biopharmaceutical company specializing in botulinum toxin-based drugs for therapeutic use. Its value is determined by its intellectual property and clinical trial results. The chart shows a high valuation per employee, as the market sees great potential in its neuroscience developments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772664607058 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company AEON Biopharma (AEON)
AEON Biopharma is a clinical-stage company developing botulinum toxin (Botox) for therapeutic and neurological purposes. As with most biotechs without an approved product, this chart reflects the intensity of R&D. It shows the loss per employee—a direct consequence of the high costs of scientists and doctors conducting clinical trials.
%20Chart%20AEON%20Biopharma%20(AEON)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-AEON-Biopharma-AEON&v=1772664607068 "Company Profit Per Employee (in thousands of dollars) Chart AEON Biopharma (AEON)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
AEON Biopharma specializes in botulinum toxin-based therapeutics for neurological diseases. In the pharmaceutical industry, high employee productivity is often associated with owning patents for in-demand drugs. This chart allows us to assess how effective the company's business model is in generating profit per employee compared to other players in the pharmaceutical industry.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772664607081 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
AEON Biopharma is a biotech company specializing in the therapeutic use of botulinum toxin (similar to Botox) for the treatment of neurological disorders. As with any biotech company, their staff consists primarily of scientists. This chart, showing the average market profitability per employee, helps clarify the contrast with R&D businesses, where capital is invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772664607085 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee AEON Biopharma (AEON)
AEON Biopharma is a biopharmaceutical company developing therapeutic applications for botulinum toxin. This metric may be low during the clinical trials phase. However, it demonstrates potential: a successful launch will lead to explosive growth in revenue per employee, reflecting the high cost of their development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-AEON-Biopharma-AEON&v=1772664607088 "Sales chart per company employee AEON Biopharma (AEON)")
Sales per employee in the market segment - Pharma neurology
AEON Biopharma is a clinical-stage biotech developing botulinum toxin (a Botox analog) for therapeutic rather than cosmetic use (neurology). The company has no sales yet. This chart shows the average revenue per employee in the sector. For AEON, this is a benchmark: it demonstrates the effectiveness of R&D personnel expenditures compared to competitors and the target productivity level.
Sales per employee for the market as a whole
AEON Biopharma is a biotech company developing botulinum toxin for therapeutic, rather than cosmetic, use. The company's entire value lies in R&D and clinical trials. This chart reflects their current status: the company is in the research investment stage, and revenue is not yet their primary goal.
Short shares by company, segment and market as a whole
Shares shorted by company AEON Biopharma (AEON)
AEON Biopharma (AEON) is developing botulinum toxin (a Botox analog), but for therapeutic rather than cosmetic use, such as treating migraines. This chart shows the number of short positions. These short positions may be betting that the company will fail to demonstrate the superiority of its product over existing ones or that competition from AbbVie (the owner of Botox) will be too intense.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-AEON-Biopharma-AEON&v=1772664607195 "Short Shares Chart for the Company AEON Biopharma (AEON)")
Shares shorted by market segment - Pharma neurology
AEON Biopharma (AEON) specializes in the therapeutic use of botulinum toxin (a Botox analog) for the treatment of neurological conditions such as migraines. This chart aggregates short positions across the neuroscience-focused biotech sector. It reflects the high level of risk and investor skepticism regarding the complexity of developments in this field.
Shares shorted by the overall market
AEON Biopharma (AEON) is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator AEON Biopharma (AEON)
AEON Biopharma (AEON) is developing botulinum toxin (a Botox analog) for therapeutic applications, such as migraine treatment. It's a large market, but with significant competition. This oscillator measures momentum. It helps identify when the stock is overbought (above 70) on positive data or oversold (below 30) amid competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-AEON-Biopharma-AEON&v=1772664607249 "RSI 14 indicator chart for the company's stock AEON Biopharma (AEON)")
RSI 14 Market Segment - Pharma neurology
AEON Biopharma is a biopharmaceutical company developing an injectable botulinum toxin (similar to Botox) for therapeutic rather than cosmetic purposes, such as the treatment of migraines and cervical dystonia. This chart shows the overall momentum in the neurobiological segment. It helps distinguish the reaction to AEON's news from general euphoria or industry-wide panic.
RSI 14 for the overall market
AEON Biopharma (AEON) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AEON (AEON Biopharma)
AEON Biopharma is a biotech company developing botulinum toxin (ABP-450) for therapeutic, rather than cosmetic, use (for the treatment of migraines and dystonia). This chart shows the average analyst forecast. Their targets are based on clinical trial results and the potential to compete with Botox Therapeutics.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AEON-AEON-Biopharma&v=1772664607300 "A chart showing analyst consensus forecasts for the expected stock price. AEON (AEON Biopharma)")
The difference between the consensus estimate and the actual stock price AEON (AEON Biopharma)
AEON Biopharma is a biotech company trying to bring botulinum toxin (like Botox) to the therapeutic market for the treatment of migraines and other neurological conditions. This chart shows the difference between the market valuation and the consensus estimate. It shows whether experts believe they can compete with AbbVie (Botox).
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AEON-AEON-Biopharma&v=1772664607316 "A chart showing the difference between the consensus forecast and the actual stock price. AEON (AEON Biopharma)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
AEON Biopharma is a biotech company exploring the use of botulinum toxin (also known as Botox) not for wrinkles, but for treating serious conditions such as migraines and cervical dystonia. This chart shows analysts' general expectations for the neuroscience sector. It reflects whether experts believe in Botox's therapeutic potential.
Analysts' consensus forecast for the overall market share price
AEON Biopharma (AEON) – the "Botox" of treatment. They use the same botulinum toxin used in cosmetics, but for the treatment of serious conditions such as migraines and cervical dystonia. This chart shows the overall risk appetite. It reflects the market's willingness to fund R&D companies seeking new uses for known molecules.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index AEON Biopharma
AEON Biopharma is a non-cosmetic Botox company. They don't compete with Allergan; they're an R&D company developing a therapeutic botulinum toxin (ABP-450) for medical conditions (migraines, neurology). This graph is purely an indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma neurology
AEON Biopharma (AEON) is a therapeutic Botox company. The company is developing its botulinum toxin (ABP-450) not for cosmetic use, but for the treatment of neurological conditions such as chronic migraines and cervical dystonia. This chart shows the average index for the segment, helping to assess how this medical niche compares to the global market.
The AKIM Index for the overall market
AEON Biopharma is a biopharmaceutical company developing botulinum toxin for therapeutic purposes (migraine). This chart, which reflects the market average, provides a macro backdrop. It helps assess how AEON, a Botox competitor in the medical field, compares to overall economic trends.
